Trexquant Investment LP Buys New Shares in IQVIA Holdings Inc. $IQV

Trexquant Investment LP bought a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 106,556 shares of the medical research company’s stock, valued at approximately $18,786,000. Trexquant Investment LP owned 0.06% of IQVIA as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of IQV. Pacer Advisors Inc. lifted its holdings in IQVIA by 5,036.1% in the first quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company’s stock valued at $153,681,000 after buying an additional 854,732 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of IQVIA by 45.7% during the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock valued at $448,686,000 after purchasing an additional 798,534 shares during the period. D. E. Shaw & Co. Inc. raised its holdings in shares of IQVIA by 211.2% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 965,302 shares of the medical research company’s stock valued at $189,691,000 after purchasing an additional 655,153 shares during the period. Nuveen LLC acquired a new position in shares of IQVIA during the first quarter valued at about $76,328,000. Finally, Cadian Capital Management LP acquired a new position in shares of IQVIA during the fourth quarter valued at about $78,604,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,800 shares of the company’s stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider directly owned 27,178 shares of the company’s stock, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Keriann Cherofsky sold 549 shares of the company’s stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider directly owned 2,910 shares of the company’s stock, valued at $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

Analyst Upgrades and Downgrades

IQV has been the topic of several research reports. Citigroup reiterated a “neutral” rating on shares of IQVIA in a report on Thursday, May 22nd. Cowen reiterated a “buy” rating on shares of IQVIA in a report on Wednesday, July 23rd. Barclays upped their price objective on shares of IQVIA from $165.00 to $185.00 and gave the company an “equal weight” rating in a report on Wednesday, July 23rd. Redburn Partners set a $188.00 price objective on shares of IQVIA in a report on Friday, May 23rd. Finally, JPMorgan Chase & Co. decreased their target price on shares of IQVIA from $232.00 to $177.00 and set an “overweight” rating for the company in a research report on Monday, May 19th. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $228.62.

IQVIA Trading Up 0.6%

NYSE:IQV opened at $188.82 on Thursday. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $252.88. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a 50-day moving average of $175.64 and a 200-day moving average of $168.11. The company has a market cap of $32.10 billion, a PE ratio of 27.33, a PEG ratio of 2.06 and a beta of 1.30.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. During the same period in the prior year, the firm posted $2.64 EPS. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.